US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

223.00

-4.7500-2.09%

Post-market: 223.670.6685+0.30%19:53 EDT

Volume:804.92K

Turnover:174.45M

Market Cap:562.96M

PE:- -

High:224.85

Open:221.88

Low:208.28

Close:227.75

52wk High:341.93

52wk Low:102.35

Shares:2.52M

Float Shares:2.52M

Volume Ratio:1.53

T/O Rate:31.88%

Dividend:0.91

Dividend Rate:0.41%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Movement Alert｜Direxion Daily S&P Biotech Bull 3x Shares Falls 11.07% in Regular Trading, Leveraged Biotech ETF Under Pressure from Rate Hike Concerns

Health Care Roundup: Market Talk

Alignment Healthcare put volume heavy and directionally bearish

GSK's ViiV Healthcare Says HIV Treatment Cabenuva's Latest Trial Meets Primary Endpoint

MT Newswires Live

Analysts Are Bullish on Top Healthcare Stocks: Alector (ALEC), McKesson (MCK)

Conexeu provides update on FDA 510 premarket notification for Ten Minute Tissue

GSK’s ViiV Healthcare announces phase IIIb CROWN study met primary endpoint

Sector Update: Healthcare

MT Newswires Live

NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Rezolute (RZLT) and Coya Therapeutics, Inc. (COYA)

HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device

60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

BridgeBio Pharma announces FDA acceptance of oral infigratinib NDA

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

Telix Doses First US Patients With FDA-Approved Brain Cancer Imaging Drug

MT Newswires Live

BTIG Remains a Buy on AbSci (ABSI)

Analyst Reiterates Buy on Rezolute as FDA Pre-BLA Green Light and Tumor Hyperinsulinism Opportunity De-Risk Regulatory and Commercial Outlook

Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA), Xeris Pharmaceuticals (XERS) and Incyte (INCY)

Health Care Roundup: Market Talk

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Option Care Health (OPCH)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/LABU/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":223,"timestamp":1791489600000,"preClose":227.75,"halted":0,"volume":804922,"hourTrading":{"tag":"盘后","latestPrice":223.6685,"preClose":223,"latestTime":"19:53 EDT","volume":1791,"amount":398864.58336,"timestamp":1791503625102,"change":0.6685,"changeRate":0.002998,"amplitude":0.015605},"delay":0,"changeRate":-0.020856201975850714,"floatShares":2524486,"shares":2524486,"eps":0,"marketStatus":"Post-Mkt","change":-4.75,"latestTime":"10-08 19:53:47 EDT","open":221.88,"high":224.8479,"low":208.28,"amount":174446317.989,"amplitude":0.072746,"askPrice":223.8,"askSize":1,"bidPrice":222,"bidSize":5,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791504000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":227.75,"sharesOutstanding":3074486,"nav":230.529,"aum":581967299.18,"dividendRate":0.004085,"bidAskSpread":0.002401,"preHourTrading":{"tag":"盘前","latestPrice":220.18,"preClose":227.75,"latestTime":"09:29 EDT","volume":6169,"amount":1385605.45651,"timestamp":1791466199999,"change":-7.57,"changeRate":-0.033238,"amplitude":0.038727},"postHourTrading":{"tag":"盘后","latestPrice":223.6685,"preClose":223,"latestTime":"19:53 EDT","volume":1791,"amount":398864.58336,"timestamp":1791503625102,"change":0.6685,"changeRate":0.002998,"amplitude":0.015605},"volumeRatio":1.526087,"impliedVol":1.0277,"impliedVolPercentile":0.9004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2524486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.526087,"shares":2524486,"dividePrice":0.911,"high":224.8479,"amplitude":0.072746,"preClose":227.75,"low":208.28,"week52Low":102.3547,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":223,"committee":0.666667,"eps":0,"divideRate":0.004085,"volume":804922,"delay":0,"ttmEps":0,"open":221.88,"prevYearClose":159.39,"prevWeekClose":248.72,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":249.65,"twentyDayClose":266,"sixtyDayClose":277.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1192672167","title":"Movement Alert｜Direxion Daily S&P Biotech Bull 3x Shares Falls 11.07% in Regular Trading, Leveraged Biotech ETF Under Pressure from Rate Hike Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1192672167","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192672167?lang=en_us&edition=fundamental","pubTime":"2026-10-07 01:41","pubTimestamp":1791308512,"startTime":"0","endTime":"0","summary":"On October 7, Direxion Daily S&P Biotech Bull 3x Shares fell 11.07% in regular trading, trading at $228.895/share, with Turnover of $198 million.The decline reflects mounting pressure across the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Biotech Bull 3x ETF Slides as Rate Hike Fears Spike","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673570710","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2673570710","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673570710?lang=en_us&edition=fundamental","pubTime":"2026-10-07 00:20","pubTimestamp":1791303600,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0310 ET - Sanofi needs mergers and acquisitions to refill its la","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4585","BK4588","XBI","BK4581","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673052130","title":"Alignment Healthcare put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2673052130","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673052130?lang=en_us&edition=fundamental","pubTime":"2026-10-06 22:55","pubTimestamp":1791298526,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Alignment Healthcare (ALHC) with 4,339 puts trading, or 4x expected. Most active are Oct-26 10 puts and Oct-26 7.5 puts, with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alignment-healthcare-put-volume-heavy-and-directionally-bearish-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alignment-healthcare-put-volume-heavy-and-directionally-bearish-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LABU","XBI","BK4585","BK4588","BK4581","BK4154","XLV","ALHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673054830","title":"GSK's ViiV Healthcare Says HIV Treatment Cabenuva's Latest Trial Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2673054830","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673054830?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:42","pubTimestamp":1791294162,"startTime":"0","endTime":"0","summary":"ViiV Healthcare, which is majority owned by GSK , said Tuesday that a phase 3b study has met its primary endpoint, showing that at six months, Cabenuva saw \"superior rates of viral suppression\" compared with oral antiretroviral therapy in adults and adolescents with HIV-1, who had detectable virus when they started the trial.The trial has enrolled 326 participants in eight countries at 85 study sites, the company said.The results follow a previous trial that showed that Cabenuva was superior to daily oral therapy in keeping viral suppression for people with HIV who had reached viral suppression on oral antiretroviral therapy but had a history of adherence challenges, ViiV said.The latest trial addressed a \"remaining evidence gap by evaluating direct initiation of the regimen in people who still had detectable virus at study entry,\" the company said.ViiV said the latest results will now be shared with health regulators.Price: 46.77, Change: +0.24, Percent Change: +0.52","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0128526141.USD","BK4581","BK4137","GSK","BK4585","LU1829250122.USD","LABU","GSKH","BK4588","LU0029874061.USD","GSK.UK","XBI","XLV","BK4007","HCSG","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673051007","title":"Analysts Are Bullish on Top Healthcare Stocks: Alector (ALEC), McKesson (MCK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673051007","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673051007?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:30","pubTimestamp":1791293429,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alector (ALEC) and McKesson (MCK) with bullish senti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-alector-alec-mckesson-mck-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-alector-alec-mckesson-mck-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","LU0251131958.USD","LU0203347892.USD","LU0965509283.SGD","LU0742534661.SGD","LU2112291526.USD","LU1037948897.HKD","LU1506573853.SGD","LU1934455194.USD","LU0689626769.HKD","LU1023059063.AUD","MCK","LU0942090050.USD","LU0965508806.USD","LU1983260115.SGD","BK4585","LU2324357040.USD","LU0029874061.USD","LU0965509010.AUD","LU0965509101.SGD","HCSG","LU0868494617.USD","LU1585245621.USD","LU0251142724.SGD","LU0861579265.USD","LU0203345920.USD","LU2089984988.USD","LU1814569148.SGD","LU1934455863.HKD","LU0122379950.USD","BK4533","XBI","LU1061106388.HKD","LU0048573561.USD","LU0124676726.USD","BK4581","LU1366192091.USD","LABU","BK4588","LU0868494708.USD","LU1430594728.SGD","BK4139","LU1934455277.USD","XLV","LU0882574055.USD","BK4175","LU1037948541.HKD","LU0342679015.USD","LU0114720955.EUR","ALEC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673051138","title":"Conexeu provides update on FDA 510 premarket notification for Ten Minute Tissue","url":"https://stock-news.laohu8.com/highlight/detail?id=2673051138","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673051138?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:12","pubTimestamp":1791292341,"startTime":"0","endTime":"0","summary":"Conexeu Sciences (CNXU) provided an update on the regulatory and manufacturing program supporting its planned FDA 510 premarket notification for Te...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/conexeu-provides-update-on-fda-510-premarket-notification-for-ten-minute-tissue-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/conexeu-provides-update-on-fda-510-premarket-notification-for-ten-minute-tissue-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNXU","LABU","EES","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673051943","title":"GSK’s ViiV Healthcare announces phase IIIb CROWN study met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2673051943","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673051943?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:10","pubTimestamp":1791292244,"startTime":"0","endTime":"0","summary":"ViiV Healthcare, the global specialist HIV company majority owned by GSK (GSK), with Shionogi as a shareholder, announced the phase IIIb CROWN stud...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsks-viiv-healthcare-announces-phase-iiib-crown-study-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsks-viiv-healthcare-announces-phase-iiib-crown-study-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK.UK","LU0128526141.USD","XLV","HCSG","BK4007","GSK","BK4581","XBI","LABU","BK4137","BK4532","BK4588","LU1829250122.USD","GSKH","LU0029874061.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673518090","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2673518090","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673518090?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:05","pubTimestamp":1791291902,"startTime":"0","endTime":"0","summary":"Healthcare stocks were steady to higher premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF  up 0.3% and the iShares Biotechnology ETF  unchanged.McKesson  and CD&R have entered into a definitive agreement to acquire Option Care Health  for $32.05 per share, reflecting a total enterprise value of about $5.8 billion, the companies said. Shares of Option Care Health were nearly 33% higher pre-bell.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0942090050.USD","LU0861579265.USD","LU0965509101.SGD","BK4585","LU0122379950.USD","LU1934455277.USD","LU0124676726.USD","LU1934455863.HKD","LU0251131958.USD","BK4588","LABU","LU0128526141.USD","LU0742534661.SGD","HCSG","LU1057294990.SGD","LU2089984988.USD","OPCH","LU0029874061.USD","LU0432979614.USD","LU0203347892.USD","BK4581","LU1037948541.HKD","LU0314106906.USD","LU0965508806.USD","LU1585245621.USD","LU1430594728.SGD","IBB","LU1023059063.AUD","XLV","LU1983260115.SGD","XBI","LU0882574055.USD","LU1037948897.HKD","BK4137","LU0048573561.USD","LU0965509010.AUD","LU2324357040.USD","LU1814569148.SGD","LU0203345920.USD","MCK","LU0965509283.SGD","LU1366192091.USD","LU0012050646.USD","LU0342679015.USD","LU0106261612.USD","BK4175","LU2112291526.USD","BK4196","LU0689626769.HKD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673051801","title":"NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt","url":"https://stock-news.laohu8.com/highlight/detail?id=2673051801","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673051801?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:02","pubTimestamp":1791291720,"startTime":"0","endTime":"0","summary":"Roth Capital’s recent Buy initiation adds to the Anticipation Surrounding Expected October FDA discussion and NeOnc’s scheduled November 17 meetingDENVER, Oct.  06, 2026 (GLOBE NEWSWIRE) -- (247market","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/06/3375600/0/en/neonc-s-fda-catalyst-run-could-give-nthi-a-serious-jolt.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007","LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673059738","title":"Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Rezolute (RZLT) and Coya Therapeutics, Inc. (COYA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673059738","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673059738?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:50","pubTimestamp":1791291015,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Roche Holding AG (RHHVF), Rezolute (RZLT) and Coya T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-roche-holding-ag-otherrhhvf-rezolute-rzlt-and-coya-therapeutics-inc-coya-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-roche-holding-ag-otherrhhvf-rezolute-rzlt-and-coya-therapeutics-inc-coya-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","LU2293690249.USD","BK4581","LU1046234339.USD","BK4137","BK4007","BK4585","RZLT","BK4139","RHHVF","LU2539964713.USD","HCSG","COYA","XLV","LU0128526141.USD","LU2293690082.USD","XBI","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673051845","title":"HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2673051845","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673051845?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:30","pubTimestamp":1791289800,"startTime":"0","endTime":"0","summary":"Southlake, TX, Oct.  06, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.(Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/06/3375495/0/en/heartsciences-receives-fda-510-k-clearance-for-its-myovista-wavecgtm-device.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LABU","BK4585","TCAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673051818","title":"60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2673051818","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673051818?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:10","pubTimestamp":1791288600,"startTime":"0","endTime":"0","summary":"After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/06/3375462/0/en/60-degrees-pharmaceuticals-plans-january-2027-hospitalized-babesiosis-data-readout-will-seek-pre-snda-meeting-with-fda.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAT","LABU","BK4007","SXTP","BK4144","BK4585","BK4588","PRTO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673805509","title":"BridgeBio Pharma announces FDA acceptance of oral infigratinib NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2673805509","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673805509?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:40","pubTimestamp":1791286842,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma (BBIO) announced the FDA has accepted for filing its new drug application, or NDA, with Priority Review for oral infigratinib for ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bridgebio-pharma-announces-fda-acceptance-of-oral-infigratinib-nda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bridgebio-pharma-announces-fda-acceptance-of-oral-infigratinib-nda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4139","BBIO","BK4505","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673055911","title":"BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2673055911","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673055911?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:30","pubTimestamp":1791286200,"startTime":"0","endTime":"0","summary":"- Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic opt","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/06/3375352/0/en/bridgebio-announces-fda-acceptance-and-priority-review-of-nda-for-oral-infigratinib-for-children-with-achondroplasia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4156","SPRE","BK4585","BK4081","EMA","LABU","BK4588","MAA","BK4215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673055551","title":"Telix Doses First US Patients With FDA-Approved Brain Cancer Imaging Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2673055551","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673055551?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:25","pubTimestamp":1791285937,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said Tuesday it administered the first US doses of Pixclara, a Food and Drug Administration-approved positron emission tomography imaging drug for brain cancer imaging.The initial doses took place at medical centers in Cleveland and Indianapolis, starting the product's commercial availability in the country, the company said.PharmaLogic will be the manufacturing and pharmacy distribution partner to supply finished unit doses to the market, Telix said.The drug, also known as floretyrosine F-18, is used to help differentiate recurrent or progressive glioma from treatment-related changes in patients aged one month and above, it said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4588","BK4139","TLX","BK4585","TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673705344","title":"BTIG Remains a Buy on AbSci (ABSI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673705344","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673705344?lang=en_us&edition=fundamental","pubTime":"2026-10-06 18:57","pubTimestamp":1791284248,"startTime":"0","endTime":"0","summary":"In a report released today, Kambiz Yazdi from BTIG reiterated a Buy rating on AbSci, with a price target of $16.00. Yazdi covers the Healthcare sec...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-remains-a-buy-on-absci-absi-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-remains-a-buy-on-absci-absi-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BK4121","LABU","XBI","ABSI","BK4539","BK4588","ARKG","BK4581","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673058865","title":"Analyst Reiterates Buy on Rezolute as FDA Pre-BLA Green Light and Tumor Hyperinsulinism Opportunity De-Risk Regulatory and Commercial Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2673058865","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673058865?lang=en_us&edition=fundamental","pubTime":"2026-10-06 17:55","pubTimestamp":1791280554,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Julian Harrison from BTIG reiterated a Buy rating on Rezolute, with a price target of $6.00. Julian Harrison has gi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-rezolute-as-fda-pre-bla-green-light-and-tumor-hyperinsulinism-opportunity-de-risk-regulatory-and-commercial-outlook-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-rezolute-as-fda-pre-bla-green-light-and-tumor-hyperinsulinism-opportunity-de-risk-regulatory-and-commercial-outlook-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673030180","title":"Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA), Xeris Pharmaceuticals (XERS) and Incyte (INCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673030180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673030180?lang=en_us&edition=fundamental","pubTime":"2026-10-06 17:30","pubTimestamp":1791279015,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Establishment Labs Holdings (ESTA), Xeris Pharmaceut...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-establishment-labs-holdings-esta-xeris-pharmaceuticals-xers-and-incyte-incy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-establishment-labs-holdings-esta-xeris-pharmaceuticals-xers-and-incyte-incy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU2324357040.USD","HCSG","LABU","XERS","LU0128526141.USD","ESTA","BK4137","BK4007","XBI","BK4550","BK4588","XLV","IDNA","INCY","BK4198","BK4532","LU0029874061.USD","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673032178","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2673032178","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673032178?lang=en_us&edition=fundamental","pubTime":"2026-10-06 16:20","pubTimestamp":1791274800,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0710 GMT - Sanofi needs mergers and acquisitions to refill its l","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","LABU","XBI","BK4585","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673032313","title":"Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Option Care Health (OPCH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673032313","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673032313?lang=en_us&edition=fundamental","pubTime":"2026-10-06 15:40","pubTimestamp":1791272431,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sanofi (SNYNF) and Option Care Health (OPCH) with bu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-sanofi-othersnynf-and-option-care-health-opch-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-sanofi-othersnynf-and-option-care-health-opch-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4196","BK4588","BK4581","BK4137","LABU","LU0128526141.USD","LU2065731478.USD","SNYNF","HCSG","LU0012050646.USD","LU0029874061.USD","OPCH","LU0106261612.USD","BK4585","XBI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":22,"pageCount":6,"totalSize":428,"code":"91000000","status":"200"}]}}